The assessment of cachexia has evolved, with the development of various scoring systems and biomarkers for more precise evaluation, including the body mass index (BMI) adjusted weight loss grading system (WLGS) [11], the cachexia score (CASCO) [12], and an inflammation marker (C-reactive protein and albumin concentrations) as part of the Glasgow prognostic score (GPS) [13,14,15]. The gene discussed is ALB; the disease is Cachexia.